Screener / SEC EDGAR /CIK 0001759655 /10-K filed Feb 27, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Health Services

Privia Health Group, Inc. PRVA

Compare with peers Embed
The 10-K against last year's

222 changes: 11 added, 34 removed, 170 reworded, 7 quiet changes

10-K Feb 27, 2026 vs Feb 27, 2025

10-K 0001759655-26-000010 (Feb 27, 2026) vs 10-K 0001759655-25-000018 (Feb 27, 2025) Not compared: Legal Proceedings, Accounting Policies.

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

260 paragraphs · 6 new · 131 reworded · 32 gone · 10-K Feb 27, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 70 · 45% changed Every version of it
initiatives. These efforts have led to a number of investigations, prosecutions, convictions and settlements in our industry in general, including under federal civil and criminal false claims laws. Further, under the FCA and some similar state laws, private parties may bring whistleblower lawsuits against companies that allegedly submit false claims for payments to, or improperly retain overpayments from, the government.
Paragraph 197 · 44% changed Every version of it
Our business utilizes, and may invest in the future in, AI, predictive analytics and other AI technologies to add AI-based applications to our offering to drive efficiencies in our business, offer new applications, upgrade our solutions and security, and enhance our capabilities. In addition, certain of our third-party vendors utilize AI in furnishing products and services to us and our Medical Groups. These efforts, including the design and introduction of new products and services or changes to existing products and services, may result in new or enhanced governmental or regulatory scrutiny, litigation, ethical concerns, or other complications that could adversely affect our business, reputation, or financial results. Further, information systems, AI and other predictive analytics are susceptible to flaws, biases, malfunctions or manipulations, which may disrupt our and our Medical Groups’ operations, result in erroneous decision-making, elevate our and our Medical Groups’ cyber risk profile, or expose us to liability. Current and future initiatives related to health care technology (including AI and other predictive algorithms), data sharing and interoperability may require changes to the operations of the Company and Company, its Medical Groups, impose new and complex compliance obligations and require investments in infrastructure. For example, HHS finalized a rule in December 2023 imposing transparency requirements for AI and other predictive algorithms that are part of certified health information technology. Federal and state legislative and regulatory bodies, including at the executive level, continue to signal increased scrutiny and potential rulemaking surrounding the creation, adoption, and leveraging of AI- based or AI-enhanced tools, systems, and functions. The Company and its Medical Groups ACOs may be subject to financial penalties or other disincentives or experience reputational damage for failure to comply with applicable laws and regulations. Changes to existing regulations, their interpretation or implementation or new regulations could impede our use of AI and also may increase our estimated costs in this area. Further, if we are not successful in our efforts to innovate, the performance of our various products, services, and business, as well as our reputation, could suffer or we could incur liability through the violation of laws or contracts to which we are a party. Any of these factors could adversely affect our business, financial condition, and results of operations.
Paragraph 255 · 44% changed Every version of it
•events beyond our control such as extreme weather and war including the ongoing conflict between Russia and Ukraine and Israel and Palestine and other global geopolitical conflicts; and
Paragraph 212 · 43% changed Every version of it
In particular, the success of our business depends, in part, on the number, specialties, and quality of Privia Physicians, the utilization practices of these physicians, maintaining good relations with these physicians, and physician expenses, such as salary and medical malpractice expenses, as well as our ability to recruit a sufficient number of Privia Providers from the overall pool of physicians and non-physician practitioners and state-level restrictions on autonomous practice by non-physician practitioners. Our operating model and growth strategy rely on aggregating a sufficient number of Privia Physicians in each Medical Group, as the number of Privia Physicians in a particular market impacts our attributed lives for VBC purposes, our costs and our Medical Groups’ costs, and our revenues from management services. The departure of a large number of Privia Physicians or certain of our Affiliated Practices could negatively impact our financial performance and ability to perform under our VBC arrangements. Further, the loss of any Privia Physician could result in that physician’s patient population shifting their care preferences to a non-Privia provider, which could negatively affect our revenues. We may not be able to recruit new providers to replace the services of the departing Privia Physician, and we may not be able to satisfy certain obligations under third-party payer programs. We and our Medical Groups may face increased challenges recruiting and retaining quality physicians as the physician population reaches retirement age, particularly if there are shortages of physicians willing and able to provide comparable services. Further, the ability to recruit and contract with physicians is closely regulated. For example, the types, amount and duration of compensation and assistance that can be provided when recruiting
Paragraph 190 · 43% changed Every version of it
Most of our third-party licenses are non-exclusive and our competitors may obtain the right to use any of the technology covered by these licenses to compete directly with us. Our use of third-party technologies exposes us to increased risks, including, but not limited to, risks associated with the integration of new technology into our solutions, the diversion of our resources from development of our own internally developed technology and our inability to generate revenue from licensed technology sufficient to offset associated acquisition and maintenance costs. In addition, if our data suppliers choose to discontinue support of the licensed technology in the future, we might not be able to modify or adapt our own solutions.
Paragraph 147 · 43% changed Every version of it
For example, we are dependent on our EMR vendor, athenahealth, Inc., with which the Privia Technology Solution is integrated, and which is utilized by most of our Medical Groups. Our business could be adversely affected if that relationship were disrupted. The Privia Technology Solution is not currently usable with other EMRs, and moving Privia Providers to another EMR provider would require considerable effort, time and expense. In addition, our dependency and the dependency of most of our Medical Groups on athenahealth, Inc., heightens risks related to service disruptions or potential cybersecurity incidents experienced by, cessation of operations of, or price increases by this vendor. Furthermore, changes to the athenahealth, Inc. platform could require us, our Medical Groups or Privia Providers to make financial or operational investments or changes to respond to such changes to the platform. A material change in our relationship with athenahealth, Inc., whether resulting from a dispute, a change in government regulation, other factor or the loss of this relationship, could impair our ability to provide services to Privia Providers and could have a material adverse effect our business, financial condition and results of operations. Additionally, service certain of the Company’s service providers, including technology or AI-related service providers, may experience service disruptions from a variety of factors outside of the Company’s control ranging from severe or extreme weather to cybersecurity incidents and geopolitical conflict, and our operations could be negatively impacted by any disruption or vulnerabilities in the services they provide resulting from such factors outside our control.
Paragraph 242 · 42% changed Every version of it
While we may at times engage in voluntary certain ESG initiatives (such as voluntary disclosures, certifications, or goals, among others) to improve the ESG profile of the Company, required disclosures or certifications), such initiatives may be costly and may not have the desired effect. Moreover, we may not be able to successfully complete such initiatives due to factors that are within or outside of our control. Even if this is not the case, our actions may subsequently be determined to be insufficient by various stakeholders, and we may be subject to investor or regulator engagement scrutiny on our ESG efforts, even if efforts. To the extent ESG matters negatively impact our reputation, it may also impede our ability to compete as effectively to attract and retain employees, which may adversely impact our operations. In addition, we continue to evaluate our ESG disclosure practices in light of increasing levels of regulation with respect to ESG matters, such initiatives are currently voluntary. as the California Corporate Climate Data Accountability Act and Climate-Related Financial Risk and similar bills under consideration in other U.S. states, which may require us to incur significant additional costs to comply, and impose increased oversight obligations on our management and board of directors.
Paragraph 138 · 41% changed Every version of it
We have experienced, and may continue to experience, rapid growth and organizational change, which has placed, and may continue to place, significant demands on our management and our operational and financial resources. We may also seek growth opportunities through strategic acquisitions and partnerships. Additionally, our organizational structure may become more complex as we improve our operational, financial and management controls, as well as our reporting systems and procedures. We may require significant capital expenditures and the allocation of valuable management resources to grow and change in these areas. We must effectively increase our headcount and continue to effectively train, manage and retain our employees. We will be unable to manage our business effectively if we are unable to alleviate the strain on resources caused by growth in a timely and successful manner. If we fail to effectively manage our anticipated growth, the quality of our services may suffer, which could negatively affect our brand and reputation and harm our ability to attract and retain Medical Groups, Privia Providers, patients and employees. If we fail to evaluate and execute new business opportunities properly, we may not achieve anticipated benefits and may incur increased costs.

MD&A

117 paragraphs · 5 new · 68 reworded · 2 gone · 10-K Feb 27, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 41 · 47% changed
Practice Collections increased 4.5% for the year ended December 31, 2024 when 2024, compared to with the same period in 2023 2023, primarily due mainly to organic growth of our healthcare delivery business and our entrances into the Ohio, South Carolina, Washington state and Indiana markets and increased 17.1% between 2022 and 2023 due mainly to organic growth of our healthcare delivery business, our at-risk Capitated revenue contracts and entrance into the Connecticut and Washington state markets. acquisitions.
Paragraph 72 · 42% changed
The provision for income taxes was $10.8 $14.2 million for the year ended December 31, 2024, 2025, compared to a $10.8 million during the comparative period in 2024. The provision for income taxes increased as a result of $8.0 million during the same period in 2023. The change was primarily attributable to reduced tax benefits stemming from share-based compensation related to stock option exercises and restricted stock unit vesting events. higher income before income taxes.
Paragraph 102 · 39% changed
Administrative fees are reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for the provision of administration and management services to Non-Owned Medical Groups. In addition, certain of our MSAs include rebates to the customers in the event that certain conditions occur. The Company estimates the transaction price using the most likely amount methodology and amounts are included in the net transaction price to the extent that it is probable that a significant reversal will not occur once any uncertainty associated with the variable consideration is subsequently resolved. Rebates of $1.8 million have been recorded for the years ended December 31, 2024, and $2.7 million for the years ended December 31, 2023 and 2022, respectively.
Paragraph 62 · 38% changed
Depreciation and amortization expenses are primarily attributable to consists of definitive-lived intangible asset amortization and depreciation of our capital investment and consist of fixed asset depreciation and amortization of intangibles considered to have definite lives. assets. We do not allocate depreciation and amortization expenses to other operating expense categories. categories within our financial statements.
Paragraph 30 · 32% changed
Our FFS revenue is primarily dependent upon the size of our provider base, payer contracted rates and patient volume. Our ability to maintain or improve pricing levels in our contracts with payers and patient volume for our providers will impact our results of operations. In addition to increasing our provider base and contracted rates over time, we also seek to increase patient volume by demonstrating the ability to provide a better patient experience that leads to higher retention rates and drives referrals to preferred, high quality and value-based providers. Our VBC revenue is primarily dependent upon the number of attributed patients in our VBC arrangements, risk levels of our payer contracts, and effective management of our patients’ total cost of care. As we grow our provider base, we also expect to increase our total number of attributed patients in existing and new markets. In addition, we intend to increase the risk levels of our value-based programs as we seek a higher revenue opportunity on a per patient basis over time.
Paragraph 40 · 31% changed
Practice Collections increased 4.5% 16.9% for the year ended December 31, 2024 2025 when compared to with the same period in 2023 2024 primarily due mainly to organic growth of our healthcare delivery business and our entrances into acquisitions. Practice Collections increased 4.5% for the Ohio, South Carolina, Washington state and Indiana markets and increased 17.1% between 2022 and 2023 due mainly to organic growth of our healthcare delivery business, our at-risk Capitated revenue contracts and entrance into the Connecticut and Washington state markets. year ended
Paragraph 82 · 30% changed
•An increase of $19.9 $38.3 million in accounts payable receivable and accrued expenses prepaid and other current assets for the year ended December 31, 2024 2025 compared to the same period in 2023 2024 of $5.0 $28.8 million, a difference of $14.9 $9.5 million. The change is primarily driven by organic growth due to an increase in FFS and entrance into new markets. VBC revenue.
Paragraph 108 · 28% changed
Under the shared savings basis, the Company is offered may earn financial incentives to increase its for increasing accountability for over the cost, quality and efficiency of the care provided to the population of attributed members. The Company is paid the financial incentives Incentive payments are earned when, for a given twelve-month measurement period, its performance on quality of care and utilization the Company meets or exceeds the quality and utilization standards set established by the payers as outlined in the contracts payer and when achieves savings are achieved for on medical costs associated with for the population of attributed members. The To determine the amount of shared savings payments, payers analyze evaluate the activities Company’s performance during the measurement period using the agreed upon agreed-upon benchmarks, metrics and performance criteria to determine the appropriate payments to the Company. criteria.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors178 words changed in this paragraph; it is 52% similar to last year's version.
In particular, the success of our business depends, in part, on the number, specialties, and quality of Privia Physicians, the utilization practices of these physicians, maintaining good relations with these physicians, and physician expenses, such as salary and medical malpractice expenses, as well as our ability to recruit a sufficient number of Privia Providers from the overall pool of physicians and non-physician practitioners and state-level restrictions on autonomous practice by non-physician practitioners. Our operating model and growth strategy rely on aggregating a sufficient number of Privia Physicians in each Medical Group, as the number of Privia Physicians in a particular market impacts our attributed lives for VBC purposes, our costs and our Medical Groups’ costs, and our revenues from management services. The departure of a large number of Privia Physicians or certain of our Affiliated Practices could negatively impact our financial performance and ability to perform under our VBC arrangements. Further, the loss of any Privia Physician could result in that physician’s patient population shifting their care preferences to a non-Privia provider, which could negatively affect our revenues. We may not be able to recruit new providers to replace the services of the departing Privia Physician, and we may not be able to satisfy certain obligations under third-party payer programs. We and our Medical Groups may face increased challenges recruiting and retaining quality physicians as the physician population reaches retirement age, particularly if there are shortages of physicians willing and able to provide comparable services. Further, the ability to recruit and contract with physicians is closely regulated. For example, the types, amount and duration of compensation and assistance that can be provided when recruiting

Source: Item 1A, 10-K 0001759655-26-000010 vs Item 1A, 10-K 0001759655-25-000018

MD&A117 words changed in this paragraph; it is 39% similar to last year's version.
rebates to the customers in the event that certain conditions occur. The Company estimates the transaction price by analyzing using the activities during most likely amount methodology and amounts are included in the relevant time period in contemplation of the agreed upon benchmarks, metrics, performance criteria, inflation trend factors, risk ratio adjustments and attribution criteria based on those and any other contractually defined factors. Revenue is not recorded until the net transaction price can be estimated by the Company and to the extent that it is probable that a significant reversal will not occur once any uncertainty associated with the variable consideration is subsequently resolved. Revenue is Rebates of $3.5 million have been recorded during for the period when years ended December 31, 2025, $1.8 million for the services are provided during a pre-set twelve-month annual measurement period. year ended December 31, 2024 and $2.7 million for the year ended December 31, 2023, respectively.

Source: Item 7, 10-K 0001759655-26-000010 vs Item 7, 10-K 0001759655-25-000018

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of PRVA's Risk Factors and MD&A, 10-K Feb 27, 2026 against 10-K Feb 27, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
•We may encounter difficulty acquiring entities or assets, face challenges integrating the operations of acquired businesses or realizing expected results or become liable for unknown or contingent liabilities as a result of acquisitions.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
We may encounter difficulty acquiring entities or assets, face challenges integrating the operations of acquired businesses or realizing expected results or become liable for unknown or contingent liabilities as a result of acquisitions.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
A component of our business strategy is making acquisitions and entering into joint ventures with other parties in the healthcare industry. If we fail to identify and successfully complete transactions to meet our strategic objectives, including as a result of healthcare regulatory or antitrust considerations or actions or as a result of any failure to successfully integrate acquired businesses and realize expected synergies, we may be placed at a competitive disadvantage or be adversely affected by negative market perceptions, any of which may have a material adverse effect on our results of operations, financial position or cash flows. Successful acquisitions also require us to efficiently and effectively integrate the acquired business into our existing operations, including our internal control environment, culture and compliance programs, such as our data security programs. For example, we may experience information technology system vulnerabilities or litigation risks in recently acquired business. We may be unable to address fully or cost-effectively contain such vulnerabilities quickly following the acquisition or at all, which could undermine integration activities or increase risks and costs. In addition, even with appropriate diligence, pre-acquisition practices of an acquired business have exposed us in the past and may expose us in the future to legal challenges and investigations that could subject us to regulatory scrutiny or reputational harm, among other risks. Even if we are ultimately successful in resolving these matters, defending such claims may be costly and result in negative publicity or reputational harm. If we cannot successfully integrate our acquired businesses and realize contemplated revenue growth opportunities, cost savings and other synergies, our business, prospects, results of operations, financial position and cash flows could be materially and adversely affected.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
term in nature, they may be more costly than expected to complete and may not deliver the expected benefits upon completion. Our failure to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems could adversely affect our results of operations, financial position and cash flow.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
any failure by us or our Medical Groups to comply with these and any other comprehensive privacy laws passed at the state or federal level may result in regulatory enforcement action, civil litigation and reputational harm.
Read it in 10-K Feb 27, 2026 at sec.gov
RemovedRisk Factors
•Negative publicity relating to our business, industry, Medical Groups or Privia Providers and evolving expectations related to ESG initiatives may have a material adverse effect on our business or financial results.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
In addition, payment policies for different types of providers and for various items and services continue to evolve, and it is difficult to predict the nature and effect of such changes. VBC arrangements often require providers to satisfy and report certain quality measures as a prerequisite to realizing value-based revenue enhancements or use quality metrics to calculate increases to or reductions in payments. Developments that slow or limit the healthcare industry’s use of VBC arrangements, or changes in the quality metrics that providers are required to report, required thresholds, or measurement methodologies, could reduce our revenues and adversely affect our business and results of operations.
Read it in 10-K Feb 27, 2025 at sec.gov
Show the other 48
RemovedRisk Factors
The principal assumptions relating to our determination of the TAM includes determining the total number of physicians in the geographic market reduced by hospital employed physicians and other Privia Physicians in the market that are unlikely to change their
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
The risks of geographic concentration could decrease as we expand the operations of the Company and its Medical Groups to other regions of the United States, but expansion is resource-intensive and we may encounter significant barriers to entry in new markets.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
We anticipate that further geographic expansion may require us to make a substantial investment of management time, capital and/or other resources. There can be no assurance that we will be able to continue to successfully expand our operations in any new geographic markets.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
Information technology is a critical component of the day-to-day business operations of the Company and its Medical Groups. Our business is highly dependent on maintaining effective information systems, in part because VBC arrangements involve extensive data
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we seek to analyze our competitors’ services, and may in the future seek to enforce our rights against potential infringers. However, the steps we have taken to protect our intellectual property rights may not be adequate to prevent infringement, misappropriation or other violations of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully protect our intellectual property rights could result in harm to our ability to compete and reduce demand for our technology. Moreover, our failure to develop and properly manage new intellectual property could adversely affect our market positions and business opportunities. Also, some of our services rely on technologies and software developed by or licensed from third parties, and we may not be able to maintain our relationships with such third parties or enter into similar relationships in the future on reasonable terms or at all.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
The AI field is complex and rapidly evolving, and we face significant competition from other companies in our industry. Our efforts in developing and deploying AI may not succeed and our competitors may be able to deploy the technology faster. We may further be
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
Most members of our management team have limited experience managing a publicly traded company, interacting with public company investors and complying with the increasingly complex laws pertaining to public companies. Our management team may not successfully or efficiently manage us as a public company that is subject to significant regulatory oversight and reporting obligations under the federal securities laws and the continuous scrutiny of securities analysts and investors. These obligations and constituents require significant attention from our senior management and could divert their attention away from the day-to-day management of our business, which could adversely affect our business, results of operations and financial condition.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
During periods of high unemployment and inflation, governmental entities often experience budget deficits as a result of increased costs and lower than expected tax collections. Budget deficits at the federal level and within some state and local government entities have had a negative impact on spending for many health and human services programs, including Medicare, Medicaid and similar programs, which represent significant payer sources for our Medical Groups. We anticipate that budget deficits, the growing magnitude of Medicare and Medicaid expenditures and the aging of the U.S. population, among other factors, will continue to place pressure on government healthcare programs. Other risks we face during periods of economic weakness and high unemployment
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedRisk Factors
Compliance with the evolving landscape of privacy, data protection and information security laws and regulations could be time-consuming and expensive and require changes to our current processes and practices, and any failure by us or our Medical Groups to comply with these and any other comprehensive privacy laws passed at the state or federal level may result in regulatory enforcement action, civil litigation and reputational harm.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Further, we, Such disruptions could hinder our Medical Groups and Privia Providers could be unable ability to implement clinical initiatives to manage healthcare conditions of patients and appropriately document patient risk profiles, and any such public health crisis could impact adversely impacting our ability to accurately project medical cost trends. trends, increase patients’ clinical disease burdens or reduce preventive care.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
In addition, advances in AI technology may exacerbate these risks, including the risk that existing intellectual property laws may not adequately protect against advances in AI technology, which may also give giving rise to a proliferation of infringement which we may not be able to address effectively, and effectively; the risk that the use of generative AI tools could result in us inadvertently disclosing trade secrets or other confidential information. information; and the risk that the use of generative AI in the creation of our source code may not be protectable under existing intellectual property laws.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Costs of medical supplies supplies, drugs and drugs other goods may continue to increase due to market pressure from pharmaceutical companies and vendors, new product releases, product shortages and other factors including import/export restrictions, such as new, expanded or retaliatory tariffs, sanctions, quotas or trade barriers (including recent recently-imposed U.S. tariffs imposed or threatened to be imposed on China, Canada and Mexico and other countries and any retaliatory reciprocal tariffs or similar actions taken by such target countries).
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
The Company and its Medical Groups are also subject to various federal and state antitrust laws that, for example, restrict exclusive contracting relationships with healthcare providers, restrict sharing of cost and pricing data, prohibit competitors from taking collective action to set commercial payer reimbursement rates, and establish integration requirements (financial risk or clinical integration) for joint ventures or healthcare networks to jointly contract with payers.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Changes in the law’s implementation, subsequent legislation and regulations, state initiatives and other factors, including potential changes to or repeal of the Affordable Care Act ACA such as a result of changes those contained in the political landscape, One Big Beautiful Bill Act of 2025 (“OBBBA”), have affected, and may continue to affect affect, the number of individuals that elect to obtain public or private health insurance or the scope of such coverage.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
If a health system partner that is the majority owner of a Non-Owned Medical Group terminates our partnership or affiliation, we may not be able to identify an alternative partner to implement the operating model or restructure in a way to retain a sufficient number of Privia Physicians, which may restrict our ability to continue operations in that market.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Expectations regarding voluntary ESG initiatives and disclosures may result in increased costs (including but not limited to increased costs related to compliance, stakeholder engagement, contracting and insurance), enhanced compliance or disclosure obligations, or other adverse impacts to our business, financial condition, or results of operations.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
The VBC revenues of the Company and Company, its Medical Groups Groups, and ACOs are subject to risks including managing established established, and any changes to, targets relative to utilization by patients, unit cost and the mix of healthcare services, services; annual fluctuations in payment terms for certain VBC arrangements, such as Medicare Advantage payment rates, rates and care coordination fees; changes in patient attribution, attribution and attribution methodologies; and changes in plan design and other terms by payers.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
If we inappropriately use or incorporate open source software subject to certain types of open source licenses that challenge the proprietary nature of our technology-enabled platform and service, the Privia Technology Solution, we may be required to re-engineer our platform, the Privia Technology Solution, discontinue the commercialization of our platform the Privia Technology Solution or take other remedial actions, any of which could adversely impact our business, financial condition condition, cash flows, and results of operations.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Our operating model and growth strategy rely on aggregating a sufficient number of Privia Physicians in each Medical Group, as the number of Privia Physicians in a particular market impacts our attributed lives for VBC purposes, our costs and our Medical Groups’ costs, and our revenues from management services.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Our operating model and growth strategy rely on aggregating a sufficient number of Privia Physicians in each Medical Group, as the number of Privia Physicians in a particular market impacts our attributed lives for VBC purposes, our costs and our Medical Groups’ costs, and our revenues from management services.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
Reductions in the quality of services furnished by our Medical Groups, Privia Providers or ACO participants could have a material materially adverse effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
In addition, any factor that diminishes our reputation or that of our management, including failing to meet the expectations of our Medical Groups, Privia Physicians, ACO participants, health system or hospital partners, patients, or payers, or any adverse publicity or litigation involving or surrounding us, one any of our Medical Groups, Privia Providers or our management, could make it substantially more difficult for us to attract new Privia Physicians, New Medical Group, or retain existing Privia Providers and Medical Groups.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
Current and future initiatives related to health care technology (including AI and other predictive algorithms), data sharing and interoperability may require changes to the operations of the Company and its Medical Groups, impose new and complex regulatory and compliance obligations and require potentially significant investments in infrastructure.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
In April 2025, we announced a partnership with Integrated Medical Services, a multi-specialty practice, to launch Privia Medical Group Arizona (“PMG AZ”). Privia acquired a majority ownership in PMG AZ.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
In December 2025, we acquired Evolent Health, Inc.’s accountable care business, adding over 120,000 attributed lives through the MSSP, as well as various commercial and Medicare Advantage programs.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
For the Years Ended December 31, 2025 2024 2023 (in thousands) Consolidated Statements of Cash Flows Data: Net cash provided by operating activities $ 163,404 $ 109,282 $ 80,785 Net cash used in investing activities (181,570) (11,978) (42,971) Net cash provided by financing activities 6,702 4,334 3,705 Net (decrease) increase in cash and cash equivalents $ (11,464) $ 101,638 $ 41,519
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
Accounting for business combinations requires us to allocate the fair value of purchase considerations to the tangible assets acquired, liabilities assumed, and intangible assets acquired based on their estimated fair values, which were determined primarily using the income method. The excess of the fair value of purchase consideration over the fair values of these identified assets and liabilities is recorded as goodwill. Such valuations require us to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, revenue growth and attrition rates, medical claims expense, cost of care expenses, operating expenses, discount rate, contract terms and useful life from acquired assets.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Allocation of purchase consideration to identifiable assets and liabilities affects our amortization expense, as acquired finite-lived intangible assets are amortized over the useful life, whereas any indefinite lived intangible assets, including goodwill, are not amortized. During the measurement period, which is not to exceed one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings. For additional details, refer to Note 3. “Business Combinations.”
Read it in 10-K Feb 27, 2026 at sec.gov
RemovedMD&A
Based upon our experience to date, we believe Privia can succeed in all reimbursement environments and payment models. The data we collected from older provider cohorts consistently suggest that we improve their performance in both FFS and VBC metrics over
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
As of December 31, 2024, the total number of Privia-owned ACOs is nine, serving beneficiaries across the District of Columbia and eleven states, including California, Connecticut, Florida, Georgia, Maryland, Montana, North Carolina, Tennessee, Texas, Virginia, and Washington state.
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedMD&A
FFS–patient care revenue and FFS-administrative services, which increased $169.5 $214.1 million and $12.3 $11.6 million, primarily attributable to the addition of new providers and an increase in visit volume; an increase in PMPM capitated revenue of $13.5 $95.5 million primarily due to increased an increase in Attributed Lives; Lives related to capitated arrangements, improved contract terms and an increase in estimated per capita revenue; shared savings revenue, which increased $9.1 $55.6 million primarily due to more Attributed Lives in Medicare programs as well as continued strong estimated performance in our value based care programs in the aggregate. aggregate; and an increase in PMPM revenue of $9.1 million primarily due to increased Attributed Lives.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Adjusted EBITDA Margin was 22.4% 27.2%, 22.4%, and 20.1% for the year years ended December 31, 2024 an increase from 20.1% for the same period 2025, 2024, and 2023, respectively, in 2023 each case due to organic growth of our medical practice business and an increase from 19.9% in 2022, due to organic inorganic growth of our medical practice business, new market entry growth in Attributed Lives and a focus on managing the investment in new expenses.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Adjusted EBITDA increased 38.8% for the year ended December 31, 2025, as compared to the same period in 2024, and 25.2% for the year ended December 31, 2024, when as compared to the same period in 2023 2023, in each case due to organic and inorganic growth of our medical practice business and growth in Attributed Lives and increased 18.7% between 2022 and 2023 due to organic growth of our medical practice business, new market entry and a focus on managing the investment in new expenses.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The increase was driven by the increase of $11.2 $6.5 million in stock-based compensation expense, which is primarily related to an additional quarter of expense due to timing of the 2023 equity awards being granted during the second quarter of 2023 compared to 2024 equity awards being granted during the first quarter of 2024, an increase in salaries and benefits of $1.7 $3.6 million and an increase in professional services of $1.1 $2.4 million related to additional consulting services.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The increase was driven by an increase in salaries and benefits of $11.2 million related to continued growth, $11.4 million, an increase in stock-based compensation expense of $6.8 $6.6 million, primarily related to an increase in stock-based awards granted in 2024 2025 compared to 2023, 2024, and an increase of $6.1 million in platform costs of $6.5 million professional services primarily due to an increase continued growth in Implemented Providers and an increase in consulting costs of $3.3 million due to continued growth and market expansion.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The Company is paid the financial incentives Incentive payments are earned when, for a given twelve-month measurement period, its performance on quality of care and utilization the Company meets or exceeds the quality and utilization standards set established by the payers as outlined in the contracts payer and when achieves savings are achieved for on medical costs associated with for the population of attributed members.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
As a percentage of revenue, Care Margin was 23.3% for the year ended December 31, in 2024 an increase from 21.7% for the same period in 2023 2023, due to renegotiated certain at-risk capitation agreements for a more favorable contract structure which is reflected on a net basis under shared savings starting in 2024 and a decrease from 22.5% in 2022, due to the addition of the at-risk capitation arrangements during 2022 and 2023 resulting in higher revenues. 2024.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
For the Years Ended December 31, (unaudited and amounts in thousands) 2025 2024 2023 2022 Net income (loss) attributable to Privia Health Group, Inc. $ 22,919 $ 14,385 $ 23,079 $ (8,585) Net income (loss) attributable to non-controlling interests 6,807 2,659 (2,051) (3,479) Provision for (benefit from) income taxes 14,212 10,826 7,993 (6,516) Interest income, net (9,703) (10,888) (8,372) (542) Depreciation and amortization 9,907 7,268 6,533 4,571 Stock-based compensation 71,068 56,680 37,098 67,359 Other expenses(1) 10,339 9,525 7,948 8,044 Adjusted EBITDA $ 125,549 $ 90,455 $ 72,228 $ 60,852 (1) Other expenses include employer taxes on equity vesting/exercises, legal, vesting and exercises, severance and retention costs and certain other non-recurring costs.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Care Margin increased 12.4% 14.4% for the year ended December 31, 2024 2025 when compared to the same period in 2023 2024 and increased 17.5% between 2023 and 2022, 12.4% as of the year ended December 31, 2024, as compared to the same period in 2023, in each case due to organic growth of our medical practice business.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Platform Contribution increased 12.8% 20.0% for the year ended December 31, 2024 2025 when compared to the same period in 2023 2024 and increased 16.8% 12.8% between 2023 2024 and 2022, 2023, in each case due to organic and inorganic growth of our medical practice business and new market entries. a change in estimate related to our Shared Savings accrual.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The To determine the amount of shared savings payments, payers analyze evaluate the activities Company’s performance during the measurement period using the agreed upon agreed-upon benchmarks, metrics and performance criteria to determine the appropriate payments to the Company. criteria.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
In addition to increasing our provider base and contracted rates over time, we also seek to increase patient volume by demonstrating the ability to provide a better patient experience that leads to higher retention rates and drives referrals to preferred, high quality and value-based providers.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesMD&A
If we are unable to raise additional capital when desired, or if we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, results of operations, and financial condition would may be adversely affected.
Read it in 10-K Feb 27, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRVA/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.